Leg ulcers: Biochemical factors

Phlebology

Volumn 15, Issue 3-4, 2000, Pages 156-161

  Coleridge Smith, P D ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Ambulatory venous hypertension; Flavonoid treatment; Microcirculation; Neutrophils; Varicose ulceration; Varicose veins

Indexed keywords

DAFLON; FLAVONOID;

CHRONIC DISEASE; CONFERENCE PAPER; DATA BASE; GENE EXPRESSION; HISTOLOGY; HUMAN; INFLAMMATION; LEG ULCER; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MEDICAL INFORMATION; MEDICAL LITERATURE; MICROCIRCULATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; SKIN CAPILLARY; SKIN FIBROSIS; ULCEROGENESIS; VEIN DISEASE;

EID: 0034459540     PISSN: 02683555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005230070015     Document Type: Conference Paper

References (35)

1. The cause of venous ulceration
2. Causes of venous ulceration: A new hypothesis
3. Release of inflammatory mediators from stimulated neutrophils
4. Oxidants from phagocytes: Agents of defense and destruction
5. Neutrophils accentuate ischemia-reperfusion injury in isolated perfused rat kidneys
6. Leukocyte effects on the vascular resistance and glomerular filtration of the isolated rat kidney at normal and low flow rates
7. Accumulation of polymorphonuclear leukocytes during three hour myocardial ischemia
8. Haemoconcentration and the accumulation of white cells in the feet during venous stasis
9. White cell accumulation in the dependent legs of patients with ambulatory venous hypertension: A possible mechanism for trophic changes in the skin
10. Leg ulcer patients: No decreased fibrinolytic response but white cell trapping after venous occlusion of the upper limb
11. Neutrophil activation in experimental venous hypertension
12. Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease
13. 2 levels and hematrocrit in chronic venous hypertension
14. Plasma elastase in venous disease
15. Plasma lactoferrin as a marker of white cell degranulation in venous disease
16. Diminished mononuclear cell function is associated with chronic venous insufficiency
17. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation
18. Randomised trial of oral aspirin for chronic venous leg ulcers
19. Clinical benchmark for healing of chronic venous ulcers
20. Pericapillary fibrin in the ulcer-bearing skin of the leg: The cause of lipodermatosclerosis and venous ulceration
21. Leukocytes: Their role in the etiopathogenesis of skin damage in venous disease
22. Cutaneous inflammation limited to the region of the ulcer in chronic venous insufficiency
23. Dermal tissue fibrosis in patients with chronic venous insufficiency is associated with increased transforming growth factor-beta1 gene expression and protein production
24. The biomechanics of leg ulceration
25. Endothelial activation in patients with chronic venous disease
26. Circulating leucocyte adhesion molecules in chronic venous insufficiency
27. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: Implications for venous ulcer formation
28. Prognostic value of markers of collagen remodelling in venous ulcers
29. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers
30. Expression of tissue-type and urokinase-type plasminogen activator activities in chronic venous leg ulcers
31. Lipodermatosclerosis and the significance of proteolytic remodelling in the pathogenesis of venous ulceration
32. The terminal complement complex is generated in chronic leg ulcers in the absence of protectin (CD59)
33. Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease: A prospective study
34. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: A pilot study
35. Post-ischaemic leukocyte-endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: Cellular mechanisms and effect of Daflon 500 mg